Collegium Pharmaceutical, Inc. COLL Jornay PM — Thereafter

Other product segments

Similar metrics at other companies

XER

XERSProduct revenue, net — Product revenue, net

$82.45M+42.6%

LXRXProduct — Net product and licensing revenue

$1.09M-13.6%

LLYNet product revenue — Revenue

$18.45B+59.1%

MIRMProduct sales, net — Product sales, net

$159.88M+43.3%

CRNXProduct revenue, net — Total Revenue

$10.31M—

GERNProduct revenue, net — Total revenues

$51.77M+31.3%

Questions, answered.

What is Collegium Pharmaceutical, Inc.'s jornay PM — thereafter?

Collegium Pharmaceutical, Inc. (COLL) reported jornay PM — thereafter of $104.78M in Q1 2026.

How has Collegium Pharmaceutical, Inc.'s jornay PM — thereafter changed year-over-year?

Collegium Pharmaceutical, Inc.'s jornay PM — thereafter decreased by 44.4% year-over-year, from $188.61M to $104.78M.

What does jornay PM — thereafter mean?

This metric represents the net product revenue and associated amortization expenses for a specific pharmaceutical product line beyond the initial launch phase. It serves as a key indicator of the product's long-term commercial viability and market adoption trajectory. Investors use this to assess the sustainability of revenue streams and the impact of intangible asset costs on segment profitability.